casirivimab+imdevimab combination therapy
R10933-10987-COV-2067
Phase 3 small_molecule terminated
Quick answer
casirivimab+imdevimab combination therapy for COVID-19 is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- COVID-19
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated